Clinical Trial Update: Belatacept in Kidney Transplantation of Moderately Sensitized Patients [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating belatacept in moderately sensitized kidney transplant patients has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Antibody-mediated Rejection
• End-stage Renal Disease

Drugs mentioned

• belatacept (belatacept)

Snippet

Sponsor: University of Wisconsin, Madison | Conditions: End Stage Renal Disease, Antibody Mediated Rejection | Phase 4 | Status: WITHDRAWN